Physiological Basis
Phosphodiesterase type 5 (PDE5) inhibitors are the pharmacological cornerstone of erectile dysfunction management, recommended as first-line therapy by the American Urological Association (AUA) and the European Association of Urology (EAU) guidelines for the majority of men with ED. The class includes sildenafil (Viagra, generic), tadalafil (Cialis, generic), vardenafil (Levitra, generic), and avanafil (Stendra). All four agents share the same fundamental mechanism: selective inhibition of the PDE5 enzyme that degrades cyclic guanosine monophosphate (cGMP) in corpus cavernosum smooth muscle cells.
During sexual stimulation, nitric oxide is released from cavernosal nerves and vascular endothelial cells. Nitric oxide activates guanylate cyclase, which converts GTP to cGMP. Elevated intracellular cGMP concentrations activate protein kinase G, which phosphorylates ion channels and calcium-handling proteins to produce smooth muscle relaxation, cavernosal arterial dilation, increased sinusoidal blood volume, and engagement of the veno-occlusive mechanism — the full haemodynamic sequence of erection. PDE5, when uninhibited, rapidly degrades cGMP, terminating this response. PDE5 inhibitors competitively block PDE5 at the cGMP binding site, amplifying and prolonging the cGMP-mediated smooth muscle relaxation response to sexual stimulation. Critically, PDE5 inhibitors do not generate erections in the absence of sexual stimulation — they require the endogenous nitric oxide signal initiated by arousal.
The four available PDE5 inhibitors differ in their pharmacokinetic profiles, selectivity ratios, dietary interactions, and duration of action. These differences have clinically meaningful implications for dosing strategy and patient lifestyle fit. Sildenafil has an onset of 30 to 60 minutes and a duration of 4 to 6 hours; it is significantly impaired by high-fat meals, which delay gastric absorption and reduce peak plasma concentration by up to 29%. Tadalafil has an onset of 30 to 60 minutes, a duration of 24 to 36 hours, and is food-independent — making it suitable for both on-demand and daily dosing. Daily low-dose tadalafil (2.5–5 mg) provides continuous background PDE5 inhibition, allowing spontaneous erectile response without pre-planned timing. Vardenafil has a pharmacological profile similar to sildenafil with slightly greater PDE5 selectivity relative to PDE6 (retinal phosphodiesterase), reducing visual side effects. Avanafil has the fastest onset of the class (15 to 30 minutes), fewer drug interactions, and a relatively brief 6-hour duration.
The Treatment Protocol
A significant proportion of men presenting for advanced ED evaluation have not been adequately optimised on PDE5 inhibitor therapy. Published data suggest that up to 50% of men who report "failure" of PDE5 inhibitor therapy have not received the appropriate dose, have not observed correct timing and fasting conditions for sildenafil, or have not attempted a sufficient number of dose trials before concluding non-response. Structured PDE5 inhibitor optimisation addresses each of these variables systematically before concluding that advanced intervention is required. The initial optimisation consultation involves a thorough review of the patient's prior PDE5 inhibitor use — agent, dose, timing relative to meals and sexual activity, concurrent alcohol consumption, and whether adequate sexual stimulation was present — and an assessment of the cardiovascular contraindication profile.
Optimisation variables include: agent selection aligned with the patient's lifestyle (daily tadalafil for men who find on-demand timing challenging; avanafil for those who require a shorter lead time); dose titration to the maximum approved dose (sildenafil 100 mg, tadalafil 20 mg on-demand or 5 mg daily, avanafil 200 mg) before concluding non-response; rigorous instruction on fasting conditions and timing for sildenafil; addressing concurrent performance anxiety with behavioural guidance or referral; and, where concurrent hypogonadism is identified, initiating testosterone replacement to restore the androgen milieu that enables full PDE5 inhibitor responsiveness. Daily tadalafil combined with Li-ESWT or other angiogenic therapy is supported by published evidence demonstrating synergistic outcomes compared to either modality alone.
Who is a Candidate
Any adult male with erectile dysfunction who does not have absolute contraindications to PDE5 inhibitor use is a candidate for optimised PDE5 inhibitor therapy. This includes men with mild, moderate, and moderate-to-severe organic ED; men with psychogenic ED; and men with post-prostatectomy ED who have residual nerve function. The majority of men with ED have not received a fully optimised PDE5 inhibitor trial before being referred for more complex or costly interventions. Guideline-concordant practice dictates that PDE5 inhibitor optimisation should precede advanced regenerative treatments unless a specific clinical contraindication exists.
Absolute contraindications are narrow but critical: concurrent use of any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate — used for angina) is an absolute contraindication due to the risk of severe, potentially fatal hypotension from synergistic vasodilation. Concurrent use of soluble guanylate cyclase stimulators (riociguat) is also absolutely contraindicated. Relative contraindications include alpha-blocker therapy (requires dose separation and initiation at the lowest available PDE5 inhibitor dose), severe hepatic impairment, and recent acute cardiac event — each requiring individual risk-benefit assessment by the treating physician in consultation with cardiology as indicated.
Expected Outcomes and Timeline
In adequately selected patients without severe vasculogenic disease or complete cavernosal nerve injury, 70 to 80% of men with mild-to-moderate erectile dysfunction achieve satisfactory erectile response with optimised PDE5 inhibitor therapy. Response is assessed after a minimum of 4 to 6 attempted uses at the therapeutic dose and correct timing conditions — a single failed attempt does not constitute non-response. Onset of subjective improvement at the optimised dose is typically experienced within 2 to 6 weeks of initiating the correct agent and dosing strategy. Non-response at the maximum approved dose, after adequate optimisation, should prompt investigation for underlying vascular aetiology (penile Doppler), hormonal insufficiency (testosterone panel), or neurogenic cause before escalation to more invasive treatments.
Long-term PDE5 inhibitor therapy is safe and does not produce tachyphylaxis (loss of effectiveness over time) in the majority of patients. Men with progressive vascular disease may experience gradually declining response over years as the underlying organic pathology advances — this is an indication for reassessment of aetiology and consideration of adjunctive angiogenic therapy, not necessarily for immediate escalation to prosthetic surgery.
Safety Profile and Risks
PDE5 inhibitors are among the most extensively studied drug classes in medicine, with a well-characterised adverse effect profile. Common class effects include headache (vasodilatory), facial flushing, nasal congestion, and dyspepsia, all attributable to smooth muscle relaxation in non-penile vascular beds. Sildenafil and vardenafil at high doses can produce transient visual disturbance — a blue-green colour tinge or increased light sensitivity — attributable to mild PDE6 inhibition in the retina; this is dose-dependent and reversible. Tadalafil is associated with myalgia and lower back pain in a subset of patients, related to PDE11 inhibition in skeletal and cardiac muscle. Priapism is a rare but recognised adverse effect requiring prompt medical attention if an erection persists beyond 4 hours.
Cost and Accessibility
Generic sildenafil and tadalafil are now among the most affordable medications in common clinical use — generic sildenafil tablets are available for as little as $0.50 to $2.00 per dose through pharmacy discount programmes; generic tadalafil daily (2.5–5 mg) costs $30 to $100 per month depending on the dispensing channel. Branded formulations are substantially more expensive. Many commercial insurance plans provide partial formulary coverage for generic PDE5 inhibitors for documented ED, though coverage limits (e.g., 6 tablets per month) vary. The primary cash cost for most patients is the specialist consultation — comprehensive sexual medicine evaluation, optimisation planning, and follow-up assessment. Daily generic tadalafil, when effective, is frequently the most economical long-term ED management strategy available.
Selecting a Qualified Provider
PDE5 inhibitor optimisation is best delivered by a physician with formal training in male sexual medicine — an ABU board-certified urologist with sexual medicine or andrological subspecialty focus, or a physician with active SMSNA membership reflecting engagement with current evidence and guideline standards. The optimisation consultation requires more than prescription writing — it requires a thorough clinical assessment of ED aetiology, cardiovascular risk stratification to assess contraindications, review of concurrent medications for interactions, and a structured follow-up plan. Physicians who proceed to advanced or expensive interventions without first ensuring that PDE5 inhibitor therapy has been adequately trialled are not following guideline-concordant care.